Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kazia Therapeutics Limited
KZIA | US
0.56
USD0.06
11.78%
KZIA | US
About Kazia Therapeutics Limited
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/12/2023
As of date
21/10/2024
Close
0.56
Open
0.52
High
0.65
Low
0.51
Kazia Therapeutics Limited an oncology-focused biotechnology company develops anti-cancer drugs. Its lead development candidate is Paxalisib a small molecule brain-penetrant inhibitor of the PI3K/Akt/mTor pathway which is developed as a potential therapy for glioblastoma. It is also developing EVT801 an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney Australia.
View LessKZIA | US
Risk
230.0
Sharpe
-0.07
Luna's Score
58/100
Recommendation
Hold
Luna says (KZIA | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
309.6%1 month
230.0%3 months
163.8%6 months
399.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.76
Debt to equity
0.07
Debt to assets
0.01
Ent. to EBITDA
-0.71
Ent. to rev.
0.94
PEG
-
Other Fundamentals
EBITDA
-17.52M
MarketCap
18.69M
MarketCap(USD)
18.69M
Div. yield
-
Op. margin
-100.00M
Erngs. growth
-
Rev. growth
35.60
Ret. on equity
-186.37
Short ratio
0.20
Short perc.
1.00
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.32
Range1M
0.34
Range3M
0.35
Volumes: Market Activity
Rel. volume
2.02
Price X volume
1.88M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.71 | - | Cheaper |
| Ent. to Revenue | 0.94 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.76 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 163.82 | - | Riskier |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 18.69M | - | Emerging |
